![](jpg/gettyimages-1280895783-150x150.jpg)
Canada
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Canadian Showcase at MedCity INVEST Champions Healthcare Innovation
Presented by the Consulate General of Canada, the Canadian healthcare startup showcase included five companies. Technologies included a patient transfer solution, care coordination, women’s health, exercise tracking and remote monitoring for dysphagia, and mental health support.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Why Should U.S. Companies Consider Public Venture Capital?
The MedCity INVEST conference included a panel discussion on raising public venture capital in Canada, sponsored by Cozen O’Connor and TSX.
-
FDA Approves Bausch + Lomb Drug With a New Approach to Dry Eye Disease
Bausch + Lomb drug Miebo is now FDA approved as a new treatment for dry eye disease. Unlike many products that rewet the eye, Miebo is designed to address one of the factors that leads to dry eyes.
-
MedCity INVEST Spotlight: Get Ready for the Canadian Healthcare Startup Showcase
Five companies will take part in the showcase with technologies addressing mental health, care coordination, aging in place, physical therapy and more. Register for INVEST, scheduled for May 22-24, at the Ritz Carlton in Chicago!
-
Canada and the Midwest in Life Sciences, 75 Years in the Making
The Consulate General of Canada in Chicago is currently celebrating the 75th anniversary of its diplomatic presence in the Midwest.
-
Artificial Intelligence, BioPharma
AI Biotech Recursion Commits $88M to a Pair of Drug Discovery Acquisitions
Recursion Pharmaceuticals is acquiring two Canada-based artificial intelligence startups, Cyclica and Valence. The “biology-first company” says both deals build up its capability to apply AI to the chemistry side of drug discovery.
-
4 reasons to go public in Canada
At the MedCity INVEST conference this week, a panel discussion highlighted the benefits of going public in Canada as an alternative path for young growth stage companies to raise capital.
-
Prompt Health is creating marketplace for smart referrals
Founder and CEO Hedieh Safiyari talks about the Canadian healthcare startup on a mission to revolutionize the health and wellness experience.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
CanSino Biologics may start clinical development of Covid-19 vaccine in Canada
The Tianjin, China-based company and a Canadian federal research institution plan to advance bioprocessing and clinical development of Ad5-nCoV in Canada. CanSinoBIO is currently running a Phase II clinical trial in China.
-
Precision OS replaces cadavers for surgical spine training at the Global Spine Congress
The immersive medical education software company is applying its medical-grade virtual reality platform to train surgeons.
-
Merck, Eisai cancer drugs win approval in three countries under new regulatory initiative
Drug regulators in the U.S., Canada and Australia simultaneously approved Merck’s Keytruda and Eisai’s Lenvima for advanced endometrial carcinoma following a collaborative review under a program called Project Orbis.
-
Toronto hospital partners with Mavencare to improve patient transitions
The Salvation Army Toronto Grace Health Centre will utilize the home care company’s approach and technology solutions to reduce emergency department visits and hospital readmissions.
-
How this Canadian hospital is embracing health IT
Peter Bak, CIO of Humber River Hospital in Toronto, highlighted his organization’s digital efforts around systems automation, connectivity and an analytics-focused command center.
-
Sandoz gets into the weeds with cannabis medical product manufacturer Tilray
The Canadian company’s shares reached a high price after it signed a framework agreement with Novartis’s generics arm that would enable global commercialization.